Sclerostin: a new hope for the treatment of osteoporosis
10.3969/j.issn.2095-4344.2017.36.019
- VernacularTitle:骨硬化蛋白与骨质疏松:治疗的新方向
- Author:
Shu-Dong ZHANG
1
;
Meng-Hai ZHU
;
Shi-Fei LI
;
Qi YAO
Author Information
1. 首都医科大学附属北京世纪坛医院
- From:
Chinese Journal of Tissue Engineering Research
2017;21(36):5847-5854
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Sclerostin has been shown to promote bone formation and decrease bone resorption,which provides a new idea for the treatment of osteoporosis.OBJECTIVE:To review the literatures related to sclerostin and osteoporosis,thereby providing theoretical basis for sclerostin applied in the treatment and prevention of osteoporosis,so as to improve the diagnosis and curative efficacy of osteoporosis.METHODS:PubMed database was searched using the keywords of "osteoporosis,sclerostin,sclerosteosis,Wnt/β-catenin,LRP5/6,sclerostin antibody,sclerostin and expertise,romosozumab,blosozumab".Finally,58 pertinent articles were enrolled for analysis.RESULTS AND CONCLUSION:Sclerostin inhibits bone formation,so anti-sclerostin antibody is utilized,and animal experiments and clinical trials have shown that it can promote bone formation and inhibit bone reaorption.Phase Ⅲ trial results potentially signify a significant step in achieving market approval,which support the preclinical and clinical emergence of sclerostin antibody therapies for both osteoporosis and alternative applications.The serum level of sclerostin is found to be closely related to lifestyle,but still need to be studied in depth.Increasing trial results show that sclerostin is the promising therapeutic candidate,which provides a new direction in the prevention and treatment of osteoporosis.
